



**Figure S1** *miR-188-3p* expression in serum samples and ROC analysis for patients with AS. (A) *miR-188-3p* expression in serum samples from patients with AS and healthy individuals (normal). N=20. \*\*P<0.01 (*t*-test). (B) ROC curve analysis of *miR-188-3p* value in predicting the risk of AS. AUC =0.78. ROC, receiver operating characteristic; AS, atherosclerosis; AUC, area under the receiver operating characteristic curve.



**Figure S2** Targeted sponging of *miR-188-3p* by *RASSF8-AS1* regulated Ki-67 protein expression in ox-LDL-treated HA-VSMCs. Ki-67 protein expression in HA-VSMCs transfected with sh-lncRNA or miR inhibitor and treated by 75  $\mu$ g/mL ox-LDL. N=3. \*\*\*P<0.001 (*t*-test). ox-LDL, oxidized low-density lipoprotein; HA-VSMC, human aortic vascular smooth muscle cell; sh-lncRNA, short hairpin *RASSF8-AS1*; miR inhibitor, miR-188-3p inhibitor.

**Figure S3** *miR-188-3p* expression in HA-VSMCs transfected with *miR-188-3p* mimics or inhibitor. N=3. \*\*\*P<0.001 (*t* test). HA-VSMC, human aortic vascular smooth muscle cell; miR inhibitor, miR-188-3p inhibitor; miR mimic, miR-188-3p mimic; NC, negative control.



**Figure S4** *ATG7* expression in HA-VSMCs transfected with *miR-188-3p* mimics and treated with ox-LDL. N=3. \*\*P<0.01 (*t*-test). HA-VSMC, human aortic vascular smooth muscle cell; *ATG7*, autophagy-related gene 7; ox-LDL, oxidized low-density lipoprotein; miR mimic, miR-188-3p mimic.